Sharps Technology Shares Are Trading Higher After the Company Signed a 5-year $200 Million Syringe Sales Agreement With Nephron Pharmaceuticals.
Sharps Technology Shares Are Trading Higher After the Company Signed a 5-year $200 Million Syringe Sales Agreement With Nephron Pharmaceuticals.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.